11.30.-1
Sanofi
1Q Revenues: $11.4 billion (+7%)
1Q Earnings: $2.5 billion (+39%)
Comments: Pharmaceutical sales were $9.8 billion, up 9%, with Genzyme sales contributing $1.1 billion. Cerezyme sales were up 6% to $198.7 million. Myozyme/Lumizyme sales were $150.4 million, up 17%. Results were impacted by generic competition for Lovenox, down 11% to $701.6 million, Taxotere, down 62% to $200.1 million, continued competition for Plavix and Ambien CR, and the impact of EU austerity measures. The Diabetes business increased 14% to $1.8 billion driven by Lantus, up 17% to $1.5 billion. Sales from the Oncology business were $988.3 million, up 13%, driven Eloxatin, with sales of $512.2 million, up 96%.
1Q Revenues: $11.4 billion (+7%)
1Q Earnings: $2.5 billion (+39%)
Comments: Pharmaceutical sales were $9.8 billion, up 9%, with Genzyme sales contributing $1.1 billion. Cerezyme sales were up 6% to $198.7 million. Myozyme/Lumizyme sales were $150.4 million, up 17%. Results were impacted by generic competition for Lovenox, down 11% to $701.6 million, Taxotere, down 62% to $200.1 million, continued competition for Plavix and Ambien CR, and the impact of EU austerity measures. The Diabetes business increased 14% to $1.8 billion driven by Lantus, up 17% to $1.5 billion. Sales from the Oncology business were $988.3 million, up 13%, driven Eloxatin, with sales of $512.2 million, up 96%.